http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111821308-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 |
| filingDate | 2019-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111821308-B |
| titleOfInvention | Application of tripterygium wilfordii in preparation of medicine for treating non-alcoholic fatty liver disease |
| abstract | The invention discloses an application of tripterygium wilfordii (LLDT-8) in preparing a medicament for treating non-alcoholic fatty liver disease. In the application, the triptolide is used as an SCD-1 transcription inhibitor and/or a fatty acid beta oxidation related gene transcription activator, and comprises PPAR alpha, ACADL, ACADM, ACOX1 and CPT 1A. The tripterygium wilfordii can inhibit the mRNA of SCD-1, thereby inhibiting the desaturation of fatty acid and inhibiting the regeneration of lipid; meanwhile, the polypeptide can also increase mRNA of a gene related to fatty acid beta oxidation, thereby increasing the beta oxidation of fatty acid, increasing the content of beta-hydroxybutyric acid in serum, and finally inhibiting the lipid accumulation in liver by inhibiting the lipid generation and promoting the lipid oxidative decomposition. |
| priorityDate | 2019-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 251.